Dr. Federico Albrecht, MD

Dr. Albrecht practices at Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida.

Dr. Albrecht's NPI, 1366439689, was assigned on October 3, 2005. Dr. Albrecht graduated from Univ Salvador- Fac Med in 1994. Dr. Albrecht holds Florida license ME0078181.

Dr. Albrecht's primary practice is Baptist Health Baptist Hospital, at 8900 N Kendall Dr, Miami, FL 33176 in Miami-Dade County. The practice phone is (786) 596-1960.

Dr. Albrecht's primary practice is Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida. Dr. Albrecht is also affiliated with South Miami Hospital. The medical group on file is Baptist Health Medical Group Oncology. Dmand AI also links Dr. Albrecht to 3 more hospitals and 1 breast imaging center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Albrecht practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Albrecht's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Albrecht is board certified in medical oncology by the American Board of Internal Medicine. Dr. Albrecht is licensed in Florida.

Dmand AI lists chronic anemia, deep vein thrombosis (DVT), lung cancer and neutropenia among the conditions Dr. Albrecht treats.

CMS data shows 1,696 Medicare services from Dr. Albrecht across 6 procedure codes in 2024, for 266 Medicare patients. Medicare paid $93,138 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 266 Medicare patients who saw Dr. Albrecht in 2024. The largest group is 65 to 74, with 111 patients. 75% of them have cancer, and 75% have high blood pressure. 37% are also on Medicaid. Their average risk score is 2.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Albrecht's median patient age at 72, with 57% women.

In 2024, Dr. Albrecht wrote 1,026 Medicare Part D claims for 251 patients. 68% of them were for generic drugs. CMS names the drug for 894 of them, across 27 drugs with 11 or more claims each, at $4,722,093 in total drug cost. In 2023, CMS named 1,093 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Albrecht for performance year 2024, reported as part of a group. Dr. Albrecht accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Albrecht as offering telehealth.

Dmand AI links 5 papers to Dr. Albrecht, published from 2021 to 2024. 2022 was the busiest year, with 2. Dr. Albrecht has published most often in Cancers (Basel). Dr. Albrecht's most frequent co-authors are Paul Robert Kaywin, MD, Rupesh Rajesh Kotecha, MD and Minesh P. Mehta, MD.

Dmand AI links Dr. Albrecht to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung and Carcinoma, Bronchogenic. Open Payments lists research payments to Dr. Albrecht that name 1 trial.

CMS Open Payments shows 462 general payments to Dr. Albrecht from 33 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 66% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $145,672. It also lists 2 research payments totaling $889 from 2017 to 2018, naming 1 clinical trial.

Dr. Albrecht graduated from Univ Salvador- Fac Med in 1994. Dr. Albrecht is a member of ACP.

Dr. Albrecht is in network with 11 carriers, including Elevance, Aetna and United Healthcare. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.